Jean-Philippe Combal | Co-Founder And Chief Executive Officer
Vivet Therapeutics

Jean-Philippe Combal, Co-Founder And Chief Executive Officer, Vivet Therapeutics

Jean-Philippe has 28 years of experience in the pharma & biotech industries. He is a highly skilled senior executive with a broad range of experience leading global development and a successful track record of innovation and development in the area of Orphan Drugs. While Chief Operating Officer of GenSight Biologics (2014-2017), he successfully contributed and participated to investment round of more than 80M$, including a successful IPO and piloted the advancement of two major gene therapy programs from non-clinical to phase 3 pivotal trials, as well as regulatory and launch readiness strategies. Prior to his GenSight experience, from 2011 to 2014, he was Strategic Therapeutic Area Leader at Galderma extending from the preclinical stage through launch readiness activities and assessment of business development opportunities and prior to that held the role of Vice President of Drug Development at Sanofi (Ophthalmic Division after Fovea Pharmaceuticals acquisition; 2006-2011). During his early career, from 1990 to 2006, Jean-Philippe was a key leader in the research and development departments at Servier, Pierre Fabre, Fournier-Pharma/Solvay, Exonhit Therapeutics. Jean-Philippe earned his PhD in Toxicology and Pharm.D from Paris XI University and holds a Master in Strategic Marketing from ESCP Paris as well as a General Management Program from center of executive development at INSEAD.

Appearances:



Conference Day 1: Thursday 16th May 2019 @ 14:15

Manufacturing of a new Gene therapy product: from early decision to selection for Phase I to Phase III

  • Academics to CMO: early choice for long term impact?
  • Risk & Opportunities of potential options & current trends
  • What could be an industrial partnership offer without building our own plant?

Conference Day 1: Thursday 16th May 2019 @ 14:35

Implementing strategic development and innovating disruptive business models for transformative cell and gene therapies

· Prioritizing opportunities within the complex landscape of advanced therapeutics· Developing innovative healthcare business models for in-vivo and ex-vivo manufactured gene and cell therapies· Maintaining robust and sustainable growth in rare disease· Perspectives from investors, biotech and pharma
last published: 14/May/19 13:35 GMT

back to speakers

The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.

Register your pass here.